BioMarin's (BMRN -7.2%) recent secondary offers a buying opportunity ahead of the company's...

|About: BioMarin Pharmaceutical Inc. (BMRN)|By:, SA News Editor

BioMarin's (BMRN -7.2%) recent secondary offers a buying opportunity ahead of the company's trial data releases, says Citigroup. Citi notes management comments stating that the financing is not intended to support any acquisitions in the near-term, which will give the company a cleaner balance sheet and leave its pipeline potentially well funded.